540 results about "Vascular endothelium" patented technology

The invention provides a risk prediction method and system for cardiovascular and metabolic diseases. The method comprises the following steps: collecting continuous cardiovascular-metabolism time sequence data, and extracting phase delay parameters to construct a lipid transport rhythm out-of-synchronization characteristic spectrum; quantifying the topological connection strength of the gene cluster based on the three-dimensional genome interaction strength matrix, and generating a genetic prediction model; a vascular endothelial metabolism buffer attenuation trajectory is calculated through simulation, and a critical environment exposure parameter is determined by matching a genetic instability threshold value; and fusing multi-source data to construct a dynamic toughness model, calculating a phase space shrinkage rate of a vascular metabolism steady-state boundary, and triggering graded early warning. According to the technical scheme provided by the invention, ultra-early warning of cardiovascular metabolism risks is realized, and the individual intervention target spot recognition precision is improved.

The invention provides an application of a lactic acid modified histone H3 in preparation of a product for treating and / or preventing lung microvascular endothelial cell dysfunction, and the lactic acid modified histone H3 is obtained by carrying out lactic acid modification on the 14th amino acid of histone, the lung microvascular endothelial cell dysfunction is sepsis mediated lung microvascular endothelial cell dysfunction. The invention provides a new idea for the treatment of sepsis-mediated lung microvascular endothelial cell dysfunction.

The present invention belongs to the field of organoid chips. Provided is a multiple-organoid co-culture micro-fluidic chip, comprising organoid micro-fluidic chip cells, each organoid micro-fluidic chip cell being divided into an upper layer and a lower layer which are bonded to each other, the upper layer being sequentially provided with an organoid culture medium perfusion channel, a first channel barrier, an organoid culture chamber, a second channel barrier and a vascular endothelial culture channel, and the lower layer being provided with a micro-perfusion network channel. The chip ensures specific nutrition and microenvironment for each organoid and helps to maintain specific phenotypes for same. In addition, the chip can simulate in-vitro blood flowing, so as to perform signal communication and interaction between organoids, thereby fully simulating the in-vivo environment and interaction for multiple-organ diseases.

The invention discloses a pulmonary vascular endothelial barrier injury model and a construction method and application thereof, and relates to the technical field of biologication.The construction method of the pulmonary vascular endothelial barrier injury model comprises the following steps that a healthy mouse is adaptively fed for one week and then anesthetized with a medicine, oncostatin M recombinant protein is pretreated and then instilled into the lung of the mouse through an airway, and then the mouse is subjected to tumor cell apoptosis; obtaining a pulmonary vascular endothelial barrier injury model; the invention further discloses a pulmonary vascular endothelial barrier injury model, application of the model in preparation of a pulmonary vascular disease research model and application of the model in preparation of drugs for treating pulmonary vascular diseases. According to the pulmonary vascular endothelial barrier injury model as well as the construction method and the application thereof provided by the invention, the oncostatin M protein is combined with an oncostatin M receptor type II on an endothelial cell to activate a downstream signal channel, so that the endothelial barrier is damaged, a clear target spot is provided for the endothelial barrier injury, and a pulmonary injury mechanism can be deeply discussed.

The invention discloses a lung injury evaluation system based on a vascular endothelial cell protection effect, and the system comprises a sample processing module which is configured to execute sample preprocessing and multi-dimensional biomarker collection operation; the feature calculation module is connected to the sample processing module and is configured to perform endothelial function core index quantification and feature extraction operation; the data fusion module is connected to the feature calculation module and is configured to execute lung injury degree and endothelial protection efficiency association mapping operation; and the strategy generation module is connected to the data fusion module and is configured to execute a dynamic risk assessment and assessment strategy generation stage. The method has the following advantages and effects: systematic fusion and dynamic analysis of multi-source heterogeneous data are realized, and quantitative association mapping between biomarkers and iconography features is established, so that the comprehensiveness and predictive ability of state evaluation are remarkably improved.

The invention discloses a filling and repairing agent for promoting angiogenesis and a preparation method thereof, the filling and repairing agent is composed of a vascular endothelial cell supernatant, acellular matrix particles, a suspending aid and a protective agent, the vascular endothelial cell supernatant is prepared by inducing vascular endothelial cells into a tube under a low-oxygen three-dimensional condition, collecting a cell culture solution, centrifuging and concentrating; the acellular matrix particles are obtained by acellular tissue matrix, shearing, freeze-drying, liquid nitrogen grinding and collecting; according to the filling repairing agent for promoting angiogenesis, the vascular endothelial cell supernate and the acellular matrix particles are combined, the filling repairing agent contains high-concentration angiogenesis-related factors and a stable three-dimensional bionic scaffold structure, function complementation is achieved through the synergistic effect of the bioactive factors and the bionic scaffold, and the filling repairing agent for promoting angiogenesis is obtained. Therefore, the filling repair agent which can promote angiogenesis, construct a physical support framework and promote tissue repair and regeneration capacity is innovatively obtained.

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

The invention discloses a biomarker for early diagnosis of femoral head necrosis and application thereof, and relates to the technical field of biology. The biological marker is a serum mechanical gating cation channel Piezo1. The research finds that after early vascular endothelial cells of femoral head necrosis are damaged, the Piezo1 expression is reduced, so that the Piezo1 in blood is obviously reduced, that is, the serum mechanical gating cation channel Piezo1 can assist MRI to serve as a new index of femoral head necrosis; the monitoring of the level of the serum mechanical gating cation channel Piezo1 provides a new marker for the screening of early femoral head necrosis.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention discloses lactobacillus rhamnosus for improving thrombus and cerebral apoplexy as well as a product and application thereof, and relates to the technical field of microorganisms. The lactobacillus rhamnosus NHNK-604 disclosed by the invention is preserved in the China Center for Type Culture Collection on March 7, 2024, and the preservation number of the lactobacillus rhamnosus NHNK-604 is CCTCC (China Center for Type Culture Collection) NO: M 2024417. The NHNK-604 has the functions of dissolving thrombus, regulating blood coagulation factors of vascular endothelial cells, reducing inflammation and apoptosis of the vascular endothelial cells, reducing aging damage of cerebral micro-blood endothelial cells and promoting blood-brain barriers. In addition, the thallus biological membrane can increase colonization of mucoprotein and intestinal epithelial cells, and can be used for preparing products for improving thrombus and cerebral apoplexy.

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention belongs to the technical field of organoid culture, and particularly relates to a co-differentiated vascularized islet organoid and a construction method thereof. Aiming at the problems that the existing pancreatic islet organ vascularization mostly adopts a co-culture mode, the operation process is long, the difficulty is high, the randomness is realized, the uniformity is poor and the like, the invention provides the construction method of the co-differentiated vascularized pancreatic islet organ. The method comprises the following steps of: sequentially inducing and culturing directional endoderm cells, original intestinal canal cells and posterior preintestinal cells, and adding a culture medium containing VEGF (vascular endothelial growth factor), BMP4 (bone morphogenetic protein 4) and FGF2 (fibroblast growth factor 2) for culturing in subsequent induced differentiation, so as to obtain the co-differentiated vascularized islet organ. Under the condition that exogenous endothelial cells are not added, the iPS cells are directionally differentiated to generate the vascularized islet organ containing beta, alpha and delta cells and vascular endothelial cells for the first time, the vascularized islet organ is more mature than non-vascularized islet organs and has a stronger insulin secretion function, and a new thought and an experimental basis are provided for realizing functional healing of diabetes mellitus.

The invention relates to the technical field of exosomes, in particular to application of astragalus membranaceus exosomes to cell protection in the vascular endothelial cell apoptosis process. According to the application, the astragalus membranaceus exosome and the abelmoschus esculentus exosome are extracted respectively, and the influence of the two exosomes on the vascular endothelial cell apoptosis process is compared, so that the result shows that the astragalus membranaceus exosome can protect cells in the vascular endothelial cell apoptosis process.

The invention belongs to the technical field of biological medicine, and discloses a high-efficiency vascular endothelial cell targeting vesicle system, which is prepared from hemangioma stem cell derived exosome HemSCs-Exos and bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs, and is characterized in that the endothelial cell targeting vesicle system is prepared from the hemangioma stem cell derived exosome HemSCs-Exos and the bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs; meanwhile, the invention further discloses a preparation method of the vesicle system and application of the vesicle system in promoting proliferation and migration of endothelial cells. Different from existing targeting modification, the ingenious targeting relationship between the BMSCs-ABs and the endothelial cells belongs to non-special modification combination, and is simple and efficient; the fusion between the double EVs has the characteristic of realizing '1 + 1gt, 2', not only retains the treatment components of the HemSCs-Exos and the BMSCs-ABs, but also the fused eHEs has remarkable cell specificity distribution, and the fusion mode is simple and stable.

The invention discloses a preparation method and application of a response type NO release anticoagulant hydrogel material. The preparation method comprises the following steps: providing methylacryloylated recombinant collagen; providing methacrylated hyaluronic acid; providing caffeic acid arginine amide modified hyaluronic acid; the response type NO release anticoagulant hydrogel material is obtained by taking methylacryloylated recombinant collagen, methylacryloylated hyaluronic acid and caffeic acid arginine amide modified hyaluronic acid as raw materials. The prepared hydrogel material has the advantages of resisting bacteria, promoting proliferation of endothelial cells, inhibiting proliferation of smooth muscle cells, resisting inflammation, promoting angiogenesis, inhibiting thrombosis and the like, arginine can serve as an endogenous NO donor in blood to release NO molecules, and therefore the effect of promoting vascular endothelial repair is achieved, and the hydrogel material has the advantages of being capable of resisting bacteria, promoting proliferation of endothelial cells, inhibiting proliferation of smooth muscle cells, resisting inflammation, promoting angiogenesis, inhibiting thrombosis and the like. The introduced NO molecules enable the hydrogel material to have good anticoagulant performance, and the hydrogel material is expected to be used for preparing an artificial blood vessel anticoagulant coating.

The invention discloses a preparation method and processing equipment of herbal composite granules, and relates to the technical field of composite granules. Comprising the following components in parts by weight: 15-20 parts of soybean phospholipid, 10-15 parts of glutamine, 10-15 parts of L-arginine, 5-10 parts of a ginseng extract, 5-10 parts of phytosterol, 5-10 parts of xylooligosaccharide, 5-10 parts of inositol, 5-10 parts of a hawthorn extract, 5-10 parts of a blueberry extract, 5-10 parts of an acerola cherry extract, 0-5 parts of yeast beta glucan, 0-5 parts of a sea-buckthorn extract, 0-5 parts of a tartary buckwheat extract, 0-5 parts of haematococcus pluvialis and the like. The composition is innovative and breakthrough in successful application in the aspects of heart and cerebral vessels and anti-aging, and can regulate intestines, protect liver, reduce blood pressure and regulate blood fat; thrombus is melted, the vascular endothelial function is improved, and arteriosclerosis is prevented; meanwhile, the effects of resisting oxidation, resisting inflammation, resisting aging and enhancing immunity can also be achieved.

The invention provides a traditional Chinese medicine composition. Compared with the prior art, the traditional Chinese medicine composition has the advantages that the traditional Chinese medicines are reasonably matched, so that all the components have the effect of synergistically improving insomnia, and uncomfortable symptoms such as exhaustion, cognitive competence impairment and irritability of insomnia patients are improved; meanwhile, a transcriptome sequencing technology is adopted, the effect of the traditional Chinese medicine composition on signal channels of patients with insomnia and mild and moderate senile dementia is analyzed and studied, and it is found that the traditional Chinese medicine composition can remarkably reverse disease-related channels on disease-related cell models, remarkably reverse insomnia disorder channels in neuronal cells and microglia cells, and remarkably reverse insomnia disorder channels in neuronal cells and microglia cells. Disorder pathways of mild and moderate senile dementia diseases are obviously reversed in neuronal cells and vascular endothelial cells; therefore, the traditional Chinese medicine composition can be used for improving insomnia and preventing and treating mild and moderate senile dementia, and the traditional Chinese medicine composition is prepared from medicinal and edible medicinal materials and is safe and reliable.

The invention provides a theaflavin composition for treating hypertension as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a celery seed extract, a gastrodia elata extract, a parasitic loranthus extract, a centella asiatica extract, a lotus leaf extract and a licorice extract. Wherein the theaflavin can regulate blood fat, inhibit atherosclerosis and improve the vascular endothelial function; the celery seed extract inhibits the activity of angiotensin converting enzyme, and cooperates with theaflavin to regulate blood pressure; the gastrodia elata extract can calm liver wind and improve cerebral circulation; the loranthus parasiticus extract has the effects of tonifying liver and kidney and regulating water sodium metabolism; the centella asiatica extract can resist inflammation and repair vascular endothelium; the lotus leaf extract can clear heat, promote diuresis, calm the liver and suppress yang; and the licorice extract harmonizes the medicines and resists oxidation. According to the invention, theaflavin is taken as a core, multi-dimensional effects of reducing blood pressure, protecting blood vessels and resisting inflammation and oxidation are realized, and a natural and comprehensive health management scheme is provided for hypertensive patients.

The invention discloses an adipose-derived stem cell exosome compound loaded with silver nanoparticles and application of the adipose-derived stem cell exosome compound loaded with the silver nanoparticles, and ADSC-Exos loaded with the silver nanoparticles is developed by integrating AgNPs into an exosome of ADSCs. In vivo, the Exo-AgNPs can accelerate healing of infected wounds by reducing bacterial colonization and promoting collagen deposition, angiogenesis and M2 type macrophage polarization. In vitro, the Exo-AgNPs activates the functions of fibroblasts and vascular endothelial cells, and shows an excellent antibacterial property. In addition, the Exo-AgNPs induces polarization of M2 type macrophages and inhibits secretion of proinflammatory cytokines by activating autophagy. The results show that Exo-AgNPs is expected to become an ideal biological material for treating infected wounds.

The invention discloses a preparation method of a stem cell exosome chitosan compound covered stent. The stem cell exosome chitosan compound comprises a stem cell exosome and a chitosan compound. In the stem cell exosome and chitosan compound, the mass percent of chitosan is 3%-10%, and the number of the stem cell exosomes is 109-1011. Compared with a traditional covered stent, the covered material provided by the invention can resist inflammation, inhibit bacteria, protect vascular endothelial cells covered by the stent, promote tissue repair, prevent tissue adhesion, prevent fibrosis and inhibit exclusion reaction and autoimmunity.

According to the pluripotent stem cell-derived human mammary gland organoid and the construction method thereof, the human mammary gland organoid is obtained through the following multi-stage induction culture: first-stage culture: culturing for 1-3 days by using a first culture medium to obtain a surface ectoderm stage organoid expressing a surface ectoderm marker K8 / K18; second-stage culture: culturing for 1-3 days by using a second culture medium to obtain a mammary gland substrate-like organ which has bright epithelium and expresses mammary gland substrate markers EDAR and LEF1; third-stage culture: culturing for 3-5 days by using a third culture medium; fourth-stage culture: culturing for 3-5 days by using a fourth culture medium; a fifth culture medium is used for culture for 8-12 days to form an epithelial structure with basal cells and lumen cells, a mammary gland physiological microenvironment simulated by mesenchymal cells and vascular endothelial cells and a mature mammary gland organ with a lactation function. According to the invention, the mature mammary gland organ with a lactation function is successfully constructed.

The invention discloses application of nano-iron in vascular endothelial cells, and belongs to the technical field of cell engineering and genetic engineering. According to the invention, PEI coated Fe3O4 is taken as a research object, the application of PEI coated Fe3O4 in vascular endothelial cells is researched by adopting a molecular and cell biology method, and regulation of PEI coated Fe3O4 on vascular endothelial regeneration of the vascular endothelial cells after myocardial infarction is verified from multiple levels and multiple angles. The invention can provide a new reference for the recovery of cardiac functions after myocardial infarction, and has good application value.

The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells, and belongs to the technical field of biological medicine manufacturing. The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells. The present invention relates to G3BP1 that ensures the sustained expression of key adherent junction proteins (VE-cadherin, p120) by directly binding to and stabilizing the mRNA of these proteins; meanwhile, the G3BP1 is combined with the MYD88mRNA to promote the degradation of the MYD88mRNA, so that a permeability-promoting MYD88-ARNO-ARF6 signal channel is inhibited, especially under the condition of an inflammation period. Therefore, the G3BP1 regulates and maintains the integrity of the vascular barrier through double transcription, and a new treatment strategy is provided for damage repair of the functional integrity of the vascular endothelial cell barrier.

The invention belongs to the technical field of biomedicine, and relates to a method for constructing a mouse embryo-derived hypothalamic organ model and application, the invention proposes that a mouse embryo is used for constructing a hypothalamic organ for the first time, and the mouse embryo has a definite development time sequence and genetic operability; the naturally retained vascular endothelial cells and multilineage precursor cells provide unique advantages for constructing a three-dimensional organ containing multiple nucleuses such as a preoptic region, a paraventricular nucleus, an arcuate nucleus and a supraoptic nucleus, and the model not only breaks through the nucleus coverage limitation of the existing iPSCs organ, but also can be used for constructing the three-dimensional organ containing multiple nucleuses such as the preoptic region, the paraventricular nucleus, the arcuate nucleus, the supraoptic nucleus and the like by reconstructing a nerve-blood vessel unit. High-fidelity simulation of complex physiological functions of the hypothalamus is realized, and an irreplaceable technical platform is provided for mechanism analysis of neuroendocrine diseases and high-throughput screening of drugs.

The present invention discloses the application of ginseng exosomes in the preparation of nanomedicines for treating diabetic ulcer vascular lesions, and relates to the field of biomedicine. The present invention verifies through experiments that ginseng exosomes can reprogram the glycolysis process of vascular endothelial cells under high sugar conditions, and inhibit the expression of acetyl coenzyme A in cells, reduce the production of reactive oxygen species, and then promote the expression of nitric oxide synthase, thereby reducing or reversing cell apoptosis induced by high sugar. Ginseng exosomes are used as nanomedicines to prevent, treat or improve diabetic ulcer microangiopathy. The ginseng exosomes in the present invention have a simple preparation process, low cytotoxicity, high delivery efficiency, and good stability. They can be used as a new type of nanomedicine for the prevention, treatment or improvement of diseases related to diabetic vascular lesions.

The invention belongs to the technical field of biological medicines, and particularly relates to application of microRNA-21-3p as a target spot in preparation of a medicine for treating cerebral cavernous malformation. According to the application disclosed by the invention, it is determined for the first time that the microRNA-21-3p plays an important role in cerebral hemorrhage with cerebral cavernous malformation, the microRNA-21-3p can be used as a potential treatment target spot of the cerebral cavernous malformation, and the functions of vascular endothelial cells and pericytes can be effectively improved by improving the expression level of the microRNA-21-3p through a microRNA-21-3p agonist; therefore, a good effect of treating the cerebral cavernous malformation is achieved, and a theoretical basis is provided for researching a new target spot and a new strategy for treating the cerebral cavernous malformation.

The invention relates to an application of chrysin in preparation of drugs for treating mammalian NFAT2 related diseases. It is confirmed for the first time that chrysin shows significant anti-inflammatory activity in a KD mouse model and a cell injury model. This effect may be achieved by modulating NFAT2. The discovery has important significance for understanding and potentially treating the vascular endothelial injury of the Kawasaki disease, and a new insight is provided for treating the Kawasaki disease by using traditional Chinese medicines.

The invention belongs to the technical field of microfluidic organ chips, and particularly relates to an anti-cancer drug screening chip and method based on cancer cell migration and angiogenesis, the organ chip comprises at least one monitoring culture module, and the monitoring culture module comprises a vascular endothelial cell culture layer, a PET porous membrane layer and a tumor cell culture layer which are fixedly connected in sequence; the vascular endothelial cell culture layer comprises a vascular endothelial cell culture chamber, and two sides of the vascular endothelial cell culture chamber are respectively communicated with a liquid inlet I and a liquid outlet I; the tumor cell culture layer comprises a tumor cell culture chamber, one side of the tumor cell culture chamber is communicated with a liquid inlet II, the tumor cell culture chamber and the vascular endothelial cell culture chamber are correspondingly arranged and communicated, and the PET porous membrane layer is arranged between the vascular endothelial cell culture chamber and the tumor cell culture chamber; one side of the migration chamber is communicated with the other side of the tumor cell culture chamber, and the other side of the migration chamber is communicated with a liquid outlet II.

The invention discloses a 3D (three-dimensional) visual bionic intestine-blood vessel-nerve interface organ simulation chip, which is characterized in that a micro-fluidic chip is used as a platform to construct an intestinal tract-blood vessel-brain system which simulates biological transformation of perfluorinated compounds in intestinal tracts under near physiological conditions and biologically transports the perfluorinated compounds through blood vessels; a neuronal cell culture chamber, a vascular endothelial cell culture chamber and an intestinal tract cell culture chamber are respectively arranged on the micro-fluidic chip, the culture chambers are communicated through micro-columns, and the vascular endothelial cell culture chamber serves as a barrier in the middle; perfluorinated compounds enter corresponding cell culture cavities for culture through reagent injection channels of different cell culture channels, generated metabolites are discharged through the channels, and multi-organ interaction and toxicity induced by the perfluorinated compounds are analyzed. The chip can simulate an intestinal barrier structure, a blood vessel and a neural network structure, can highly simulate biological transport and transformation of a perfluorinated compound between intestines and brains, and effectively reduces cost and time.